AOTAL (acamprosate), alcohol dependence products
ALCOHOLOGY - Update
Opinions on drugs -
Posted on
Jan 17 2019
Reason for request
Renewal of inclusion
High clinical benefit in the management of alcohol dependent patients maintained
AOTAL, ESPERAL and REVIA are used to maintain abstinence in alcohol-dependent patients in the context of comprehensive management with psychological counselling.
AOTAL and REVIA are first-line treatments, while ESPERAL is a second-line treatment due to its antabuse effects.
A meta-analysis failed to show any significant differences between acamprosate and naltrexone in terms of abstinence and relapse.
Clinical Benefit
Substantial |
- |
Therapeutic use
- |